| Features: |
| Acer okamotoanum - Acer okamotoanum Extract Alternative Names: Acer okamotoanum, Ulleungdo maple Type: Botanical extract / flavonoid-rich plant product Source: Acer okamotoanum is a maple species native to Korea, particularly Ulleung Island. Experimental studies have used leaf extracts and solvent fractions, including flavonoid-rich ethyl acetate fractions. Active Constituents: Reported constituents include isoquercitrin, quercitrin, afzelin, and other phenolic and flavonoid compounds. Function: Acer okamotoanum extracts exhibit antioxidant, anti-inflammatory, cytoprotective, and neuroprotective activities. Experimental studies show reductions in reactive oxygen species, lipid peroxidation, inflammatory signaling, and apoptotic damage, together with preservation of neuronal viability and cellular stress resistance. Alzheimer's Disease: Preclinical evidence suggests potential neuroprotective and cognition-preserving effects. Acer okamotoanum extract has improved learning and memory and reduced oxidative stress in experimental models involving amyloid-β and metabolic stress. Constituents including isoquercitrin, quercitrin, and afzelin may contribute to these effects through antioxidant, anti-inflammatory, and amyloid-related mechanisms. Clinical efficacy for Alzheimer's disease has not been established. |
| Source: |
| Type: |
| BACE stands for β-site APP-cleaving enzyme, also known as β-secretase. It plays a central role in the pathogenesis of Alzheimer’s disease by initiating the production of amyloid-β (Aβ) peptides, the primary components of amyloid plaques found in the brains of individuals with AD. -inhibiting BACE1 reduces Aβ production. BACE1 - Beta-Site APP Cleaving Enzyme 1 / β-Secretase 1 Abbreviation: BACE1, β-secretase, β-secretase 1 Type: Aspartyl protease / amyloidogenic APP-processing enzyme Function: BACE1 is a membrane-associated aspartyl protease that performs the initial β-secretase cleavage of amyloid precursor protein (APP). This cleavage generates soluble APPβ and the membrane-bound C99 fragment, which is subsequently cleaved by γ-secretase to produce amyloid-β peptides including Aβ40 and Aβ42. Alzheimer's Disease: ↑ Increased BACE1 expression or enzymatic activity promotes amyloidogenic APP processing and increases amyloid-β production. Elevated BACE1 activity has been reported in Alzheimer's disease and contributes to Aβ accumulation, plaque formation, synaptic dysfunction, and disease progression. BACE1 inhibition reduces Aβ production, although clinical BACE1 inhibitors have been limited by adverse effects related to the enzyme's normal physiological functions. |
| 7839- | AO, | ISQ, | The Protective Effects of Acer okamotoanum and Isoquercitrin on Obesity and Amyloidosis in a Mouse Model |
| - | in-vivo, | AD, | NA | - | in-vivo, | Obesity, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:466 Target#:1349 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid